April 29, 2016 / 11:35 AM / 3 years ago

BRIEF-Shire says binge eating label one factor behind Vyvanse growth

April 29 (Reuters) -

* Shire CEO says remains ahead of several benchmarks on Baxalta integration planning

* Shire CEO says not updating synergy expectations on Baxalta before deal closes

* Shire CEO says Vyvanse being driven by growth in adult ADHD market and new binge eating disorder indication Source text for Eikon: Further company coverage: [ ] (Reporting by UK bureau)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below